open access
Prevention of epilepsy in humans – truth or myth? The experience from Sturge-Weber syndrome and Tuberous Sclerosis Complex
, 1, 12
Affiliations- Department of Child Neurology, Medical University of Warsaw, Żwirki i Wigury 63A, 02-091 Warsaw, Poland
- Department of Neurology and Epileptology, The Children’s Memorial Health Institute, Warsaw, Poland, Dzieci Polskich Str. 20, 04-730 Warsaw, Poland
open access
Abstract
Introduction. Epilepsy is a chronic neurological disease, usually decreasing the quality of life and often resulting in other comorbidities e.g. cognitive impairment in children. Despite the recent discovery of new antiepileptic drugs, roughly one in three patients suffers from drug-resistant seizures. Therefore, the prevention of epilepsy is becoming one of the most important challenges in medicine. Is it, however, in fact possible to prevent epilepsy?
Clinical reflections and implications. We present the results of preventive antiepileptic treatment in children with Sturge-Weber syndrome and Tuberous Sclerosis Complex as examples of the possible prevention of epilepsy and epilepsy-associated cognitive impairment in children.
Abstract
Introduction. Epilepsy is a chronic neurological disease, usually decreasing the quality of life and often resulting in other comorbidities e.g. cognitive impairment in children. Despite the recent discovery of new antiepileptic drugs, roughly one in three patients suffers from drug-resistant seizures. Therefore, the prevention of epilepsy is becoming one of the most important challenges in medicine. Is it, however, in fact possible to prevent epilepsy?
Clinical reflections and implications. We present the results of preventive antiepileptic treatment in children with Sturge-Weber syndrome and Tuberous Sclerosis Complex as examples of the possible prevention of epilepsy and epilepsy-associated cognitive impairment in children.
Keywords
epilepsy, prevention, tuberous sclerosis, Sturge-Weber
About this articleTitle
Prevention of epilepsy in humans – truth or myth? The experience from Sturge-Weber syndrome and Tuberous Sclerosis Complex
Journal
Neurologia i Neurochirurgia Polska
Issue
Article type
Review Article
Pages
190-193
Published online
2019-06-05
Page views
1409
Article views/downloads
310
DOI
Pubmed
Bibliographic record
Neurol Neurochir Pol 2019;53(3):190-193.
Keywords
epilepsy
prevention
tuberous sclerosis
Sturge-Weber
Authors
Monika Słowińska
Weronika Golec
Sergiusz Jóźwiak
References (31)- Behr C, Goltzene MA, Kosmalski G, et al. Epidemiology of epilepsy. Rev Neurol (Paris). 2016; 172(1): 27–36.
- Garcia-Ramos C, Dabbs K, Meyerand E, et al. Psychomotor slowing is associated with anomalies in baseline and prospective large scale neural networks in youth with epilepsy. Neuroimage Clin. 2018; 19: 222–231.
- Lenck-Santini PP, Scott RC. Mechanisms Responsible for Cognitive Impairment in Epilepsy. Cold Spring Harb Perspect Med. 2015; 5(10).
- Kalilani L, Sun X, Pelgrims B, et al. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. Epilepsia. 2018; 59(12): 2179–2193.
- Pitkänen A, Lukasiuk K, Dudek FE, et al. Epileptogenesis. Cold Spring Harb Perspect Med. 2015; 5(10).
- Clossen BL, Reddy DS. Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy. Biochim Biophys Acta Mol Basis Dis. 2017; 1863(6): 1519–1538.
- Graham N, Crichton S, Koutroumanidis M, et al. Incidence and Associations of Poststroke Epilepsy. Stroke. 2013; 44(3): 605–611.
- Englander J, Bushnik T, Duong TT, et al. Analyzing risk factors for late posttraumatic seizures: a prospective, multicenter investigation. Arch Phys Med Rehabil. 2003; 84(3): 365–373.
- Comi AM. Update on Sturge-Weber syndrome: diagnosis, treatment, quantitative measures, and controversies. Lymphat Res Biol. 2007; 5(4): 257–264.
- Comi AM. Sturge-Weber syndrome. Handb Clin Neurol. 2015; 132: 157–168.
- Sudarsanam A, Ardern-Holmes SL. Sturge-Weber syndrome: from the past to the present. Eur J Paediatr Neurol. 2014; 18(3): 257–266.
- Ville D, Enjolras O, Chiron C, et al. Prophylactic antiepileptic treatment in Sturge-Weber disease. Seizure. 2002; 11(3): 145–150.
- Kaseka ML, Bitton JY, Décarie JC, et al. Predictive Factors for Epilepsy in Pediatric Patients With Sturge-Weber Syndrome. Pediatr Neurol. 2016; 64: 52–58.
- Pinto A, Sahin M, Pearl PL. Epileptogenesis in neurocutaneous disorders with focus in Sturge Weber syndrome. F1000Res. 2016; 5.
- Alkonyi B, Chugani HT, Juhász C. Transient focal cortical increase of interictal glucose metabolism in Sturge-Weber syndrome: implications for epileptogenesis. Epilepsia. 2011; 52(7): 1265–1272.
- Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008; 372(9639): 657–668.
- Słowińska M, Jóźwiak S, Peron A, et al. Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures? Orphanet J Rare Dis. 2018; 13(1): 25.
- Chu-Shore CJ, Major P, Camposano S, et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010; 51(7): 1236–1241.
- Domańska-Pakieła D, Kaczorowska M, Jurkiewicz E, et al. EEG abnormalities preceding the epilepsy onset in tuberous sclerosis complex patients - a prospective study of 5 patients. Eur J Paediatr Neurol. 2014; 18(4): 458–468.
- Whitney R, Jan S, Zak M, et al. The Utility of Surveillance Electroencephalography to Guide Early Antiepileptic Drug Therapy in Infants With Tuberous Sclerosis Complex. Pediatr Neurol. 2017; 72: 76–80.
- Jóźwiak S, Kotulska K, Domańska-Pakieła D, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol. 2011; 15(5): 424–431.
- Caban C, Khan N, Hasbani DM, et al. Genetics of tuberous sclerosis complex: implications for clinical practice. Appl Clin Genet. 2017; 10: 1–8.
- Sadowski K, Kotulska-Jóźwiak K, Jóźwiak S. Role of mTOR inhibitors in epilepsy treatment. Pharmacol Rep. 2015; 67(3): 636–646.
- Salussolia CL, Klonowska K, Kwiatkowski DJ, et al. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex. Annu Rev Genomics Hum Genet. 2019 [Epub ahead of print].
- Schubert-Bast S, Rosenow F, Klein KM, et al. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives. Epilepsy Behav. 2019; 91: 94–98.
- Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013; 381(9861): 125–132.
- Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013; 381(9869): 817–824.
- McCormack FX, Inoue Y, Moss J, et al. National Institutes of Health Rare Lung Diseases Consortium, MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011; 364(17): 1595–1606.
- Jóźwiak S, Sadowski K, Kotulska K, et al. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature. Pediatr Neurol. 2016; 61: 21–27.
- French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016; 388(10056): 2153–2163.
- Jóźwiak S, Kotulska K. Prevention of epileptogenesis--a new goal for epilepsy therapy. Pediatr Neurol. 2014; 51(6): 758–759.
